VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraPro Short QQQ

Direxion Technology Bear 3X Shares

VanEck Vectors Junior Gold Miners ETF

ProShares Ultra Silver

VanEck Vectors Gold Miners ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

VS TR -1x Short VIX Futures ETF

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily Semicondct Bull 3X ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

ProShares UltraPro QQQ

Direxion Daily Technology Bull 3X ETF

ProShares UltraShort Silver

AXS 2X Innovation ETF

ProShares UltraShort Bloomberg Natrl Gas

Imunon Inc. Common Stock

Oklo Inc.

NuScale Power Corporation Class A Common Stock

ASP Isotopes Inc. Common Stock

Cameco Corporation Common Stock

SolarEdge Technologies Inc. Common Stock

Intuit Inc. Common Stock

CompoSecure Inc. Class A Common Stock

GameStop Corporation Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Siyata Mobile Inc. Common Shares

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

Navitas Semiconductor Corporation Common Stock

Trio Petroleum Corp. Common Stock

Workday Inc. Class A Common Stock

Copart Inc. (DE) Common Stock

Pony AI Inc. American Depositary Shares

Ross Stores Inc. Common Stock

MicroStrategy Incorporated Common Stock Class A

Cleveland-Cliffs Inc. Common Stock

Click here to get full coverage on Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage  Stock Titan

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan

Click here to get full coverage on Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering  GlobeNewswire

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus

Outlook Therapeutics (OTLK) Launches Public Offering of Stock an  GuruFocus

Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus

Click here to get full coverage on Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - Stock Titan

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants  Stock Titan

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - Stock Titan

Click here to get full coverage on Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants  GlobeNewswire

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire

Click here to get full coverage on OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study - Yahoo Finance

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study  Yahoo Finance

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News  GuruFocus

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus

Click here to get full coverage on Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), - Yahoo Finance

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),  Yahoo Finance

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), - Yahoo Finance

Click here to get full coverage on Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches - Stock Titan

Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches  Stock Titan

Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches - Stock Titan

Click here to get full coverage on Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus

Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News  GuruFocus

Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus

Click here to get full coverage on Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - GlobeNewswire

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration  GlobeNewswire

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus

Outlook Therapeutics (OTLK) Announces $13M Public Offering  GuruFocus

Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus

Click here to get full coverage on Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial  GlobeNewswire

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News - GuruFocus

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News  GuruFocus

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News - GuruFocus

Click here to get full coverage on Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewswire

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD  GlobeNewswire

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News - GuruFocus

Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News  GuruFocus

Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News - GuruFocus

Click here to get full coverage on Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025 - Stock Titan

Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025  Stock Titan

Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025 - Stock Titan

Click here to get full coverage on Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update  GlobeNewswire

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - Stock Titan

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint?  Stock Titan

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - Stock Titan

Click here to get full coverage on Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks

Outlook Therapeutics Announces New Stock and Warrant Offering  TipRanks

Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks

Click here to get full coverage on Outlook Therapeutics® Streamlines Operations - GlobeNewswire

Outlook Therapeutics® Streamlines Operations  GlobeNewswire

Outlook Therapeutics® Streamlines Operations - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update  GlobeNewswire

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewswire

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial  GlobeNewswire

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - Stock Titan

Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD  Stock Titan

Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - Stock Titan

Click here to get full coverage on Outlook Therapeutics' Eye Drug Falls Short in Phase 3 Trial, Misses Key Endpoint - Stock Titan

Outlook Therapeutics' Eye Drug Falls Short in Phase 3 Trial, Misses Key Endpoint  Stock Titan

Outlook Therapeutics' Eye Drug Falls Short in Phase 3 Trial, Misses Key Endpoint - Stock Titan

Click here to get full coverage on Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News - GuruFocus

Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News  GuruFocus

Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News - GuruFocus

Click here to get full coverage on Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewswire

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD  GlobeNewswire

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics announces proposed public offering of common stock, warrants - MSN

Outlook Therapeutics announces proposed public offering of common stock, warrants  MSN

Outlook Therapeutics announces proposed public offering of common stock, warrants - MSN

Click here to get full coverage on Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire

Outlook Therapeutics® Announces NICE Recommendation of  GlobeNewswire

Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire

Click here to get full coverage on Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? - Yahoo Finance

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?  Yahoo Finance

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics expands share authorization - Investing.com

Outlook Therapeutics expands share authorization  Investing.com

Outlook Therapeutics expands share authorization - Investing.com

Click here to get full coverage on Outlook Therapeutics® Announces Executive Leadership Transition - GlobeNewswire

Outlook Therapeutics® Announces Executive Leadership Transition  GlobeNewswire

Outlook Therapeutics® Announces Executive Leadership Transition - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewswire

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors  GlobeNewswire

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial  GlobeNewswire

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss  Yahoo Finance

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? - Yahoo Finance

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?  Yahoo Finance

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles  Seeking Alpha

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha

Click here to get full coverage on Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

Outlook Therapeutics, Inc. SEC 10-Q Report  TradingView

Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial - Yahoo Finance

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial  Yahoo Finance

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial - Yahoo Finance

Click here to get full coverage on Outlook Therapeutics Plunges Over 70% On Mixed Results From Wet AMD Trial - Nasdaq

Outlook Therapeutics Plunges Over 70% On Mixed Results From Wet AMD Trial  Nasdaq

Outlook Therapeutics Plunges Over 70% On Mixed Results From Wet AMD Trial - Nasdaq

Click here to get full coverage on Outlook’s shares crash as wet AMD drug flunks Phase 3 test - Endpoints News

Outlook’s shares crash as wet AMD drug flunks Phase 3 test  Endpoints News

Outlook’s shares crash as wet AMD drug flunks Phase 3 test - Endpoints News

Click here to get full coverage on Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million - GlobeNewswire

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million  GlobeNewswire

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million - GlobeNewswire

Click here to get full coverage on Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today? - InvestorPlace

Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?  InvestorPlace

Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today? - InvestorPlace

Click here to get full coverage on OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, - GlobeNewswire

OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS,  GlobeNewswire

OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, - GlobeNewswire

Click here to get full coverage on The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Outlook Therapeutics, Inc. (OTLK) Investors - Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Outlook Therapeutics, Inc. (OTLK) Investors  Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Outlook Therapeutics, Inc. (OTLK) Investors - Business Wire

Click here to get full coverage on Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 - Yahoo Finance

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010  Yahoo Finance

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 - Yahoo Finance

Click here to get full coverage on US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters

US FDA declines to approve Outlook Therapeutics' eye disease drug  Reuters

US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters

Click here to get full coverage on OTLK Stock Price and Chart — NASDAQ:OTLK - TradingView

OTLK Stock Price and Chart — NASDAQ:OTLK  TradingView

OTLK Stock Price and Chart — NASDAQ:OTLK - TradingView

Click here to get full coverage on Biotech on a Budget: 7 Stocks Under $10 With Huge Potential - InvestorPlace

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential  InvestorPlace

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential - InvestorPlace

Click here to get full coverage on Oncobiologics (OTLK) - Zacks Investment Research

Oncobiologics (OTLK)  Zacks Investment Research

Oncobiologics (OTLK) - Zacks Investment Research

Click here to get full coverage on Outlook Therapeutics (OTLK) Stock Price, News & Analysis - MarketBeat

Outlook Therapeutics (OTLK) Stock Price, News & Analysis  MarketBeat

Outlook Therapeutics (OTLK) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress - GlobeNewswire

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress  GlobeNewswire

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress - GlobeNewswire

Click here to get full coverage on Outlook Therapeutics Reports Topline Results and Positive - GlobeNewswire

Outlook Therapeutics Reports Topline Results and Positive  GlobeNewswire

OUTLOOK THERAPEUTICS INC (OTLK)

Price Chart

Key Statistics

Technicals

About OTLK

Latest News

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus

Advanced Charts

Top Gainers

Top Losers